Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Announces Closing of Strategic Collaboration with Lilly

View Press Release View All

Mar 11, 2021 • 7:30am EST

Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients

Mar 2, 2021 • 4:01pm EST

Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Feb 23, 2021 • 7:30am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update

March 2021

View Presentation

2021 Annual Meeting of Stockholders

View Event Add to Calendar View All

FY 2020

Fiscal Year Ended Dec 31, 2020

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-K

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080